Mangrove Partners’s Anebulo Pharmaceuticals ANEB Stock Holding History

Mangrove Partners’s Portfolio ANEB Stock Details ANEB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,525,252	Closed	-$2.55M	–	436
2025 Q4	$2.55M	Hold	2,525,252	–	–	0.21%	59
2025 Q3	$6.31M	Hold	2,525,252	–	–	0.47%	28
2025 Q2	$3.64M	Hold	2,525,252	–	–	0.39%	43
2025 Q1	$3.28M	Hold	2,525,252	–	–	0.35%	49
2024 Q4	$3.64M	Buy	+2,525,252	New	+$4.16M	0.4%	49
2023 Q4	–	Sell	-399,219	Closed	-$1.22M	–	176
2023 Q3	$1.22M	Hold	399,219	–	–	0.09%	120
2023 Q2	$938K	Hold	399,219	–	–	0.07%	160
2023 Q1	$1.16M	Hold	399,219	–	–	0.08%	176
2022 Q4	$968K	Hold	399,219	–	–	0.05%	249
2022 Q3	$1.12M	Hold	399,219	–	–	0.06%	256
2022 Q2	$2.08M	Hold	399,219	–	–	0.1%	291
2022 Q1	$2.83M	Sell	399,219 -7,840	-2%	-$53.7K	0.15%	233
2021 Q4	$2.5M	Sell	407,059 -9,487	-2%	-$62.9K	0.15%	215
2021 Q3	$2.73M	Sell	416,546 -11,954	-3%	-$83.8K	0.24%	137
2021 Q2	$2.92M	Buy	+428,500	New	+$3.19M	0.3%	77

Mangrove Partners's ANEB Position: Q1 2026 in Review

Mangrove Partners sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2026, closing a stake of 2,525,252 shares — an estimated $2.55M sold.

Mangrove Partners first reported a position in ANEB in Q2 2021 and held it in 15 quarters. The position peaked at $6.31M in Q3 2025. 0 funds tracked by Wall St. Rank hold ANEB as of Q1 2026.

Mangrove Partners reported no remaining Anebulo Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Mangrove Partners sold 2,525,252 Anebulo Pharmaceuticals shares in Q1 2026, an estimated $2.55M.
Mangrove Partners first reported a position in Anebulo Pharmaceuticals in Q2 2021 and held it in 15 quarters.
Mangrove Partners's Anebulo Pharmaceuticals position peaked at $6.31M in Q3 2025.
0 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.